Kynurenine pathway is altered in patients with SLE and associated with severe fatigue.

Karolina ÅkessonSusanne PetterssonSara StåhlIzabella SurowiecMattias HedenströmSusanna EketjällJohan TryggPer-Johan JakobssonIva GunnarssonElisabet SvenungssonHelena Idborg

Published in: Lupus science & medicine (2018)

Metabolites in the kynurenine pathway are altered in patients with SLE compared with controls. Interestingly, fatigue correlated weakly with measures of enhanced tryptophan metabolism, while depression did not. Drugs targeting enzymes in the kynurenine pathway, for example, IDO inhibitors or niacin (B12) supplementation, which suppresses IDO activity, merit further investigation as treatments in SLE.

Keyphrases

systemic lupus erythematosus
disease activity
sleep quality
depressive symptoms
signaling pathway
rheumatoid arthritis
early onset
cancer therapy